Aeglea culls workers, shifts pipeline focus after knockback by FDA

Aeglea BioTherapeutics’ staffers are feeling the consequences of its failed attempt to bring a rare disease drug to market. Fresh from a rare refusal-to-file letter from the FDA, the biotech has shifted its focus to an earlier-phase prospect and reduced its head count.